GlaxoSmithKline PLC ADR
$ 58.93
0.67%
13 Feb - close price
- Market Cap 117,468,832,000 USD
- Current Price $ 58.93
- High / Low $ 59.17 / 58.56
- Stock P/E 15.49
- Book Value 5.56
- EPS 3.78
- Next Earning Report 2026-04-29
- Dividend Per Share $0.66
- Dividend Yield 3.05 %
- Next Dividend Date 2026-04-09
- ROA 0.10 %
- ROE 0.43 %
- 52 Week High 60.37
- 52 Week Low 31.39
About
GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.
Analyst Target Price
$56.06
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-04 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-05 | 2024-10-30 | 2024-07-31 | 2024-05-01 | 2024-01-31 | 2023-11-01 | 2023-07-26 | 2023-04-26 |
| Reported EPS | 0.6969 | 1.4562 | 1.24 | 1.2 | 0.58 | 1.29 | 1.1 | 1.09 | 0.72 | 1.28 | 0.97 | 0.9 |
| Estimated EPS | 0.6378 | 1.17 | 1.11 | 1.04 | 0.49 | 1.16 | 0.99 | 0.91 | 0.76 | 1.14 | 0.87 | 0.82 |
| Surprise | 0.0591 | 0.2862 | 0.13 | 0.16 | 0.09 | 0.13 | 0.11 | 0.18 | -0.04 | 0.14 | 0.1 | 0.08 |
| Surprise Percentage | 9.2662% | 24.4615% | 11.7117% | 15.3846% | 18.3673% | 11.2069% | 11.1111% | 19.7802% | -5.2632% | 12.2807% | 11.4943% | 9.7561% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.2 |
| Currency | USD |
Previous Dividend Records
| Apr 2026 | Jan 2026 | Jan 1970 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | Jan 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-04-09 | 2026-01-08 | None | 2025-07-10 | 2025-04-10 | 2025-01-09 | 2024-10-10 | 2024-07-11 | 2024-04-11 | 2024-01-11 |
| Amount | $0.485604 | $0.417088 | $0.428118 | $0.429088 | $0.400652 | $0.389052 | $0.385671 | $0.376185 | $0.4060608 | $0.3397772 |
Next Dividend Records
| Dividend per share (year): | $0.66 |
| Dividend Yield | 3.05% |
| Next Dividend Date | 2026-04-09 |
| Ex-Dividend Date | 2026-02-20 |
Recent News: GSK
2026-02-11 16:27:27
GSK insider Luke Miels sold 4,549 shares of the company's stock on February 9th at an average price of GBX 2,211, totaling £100,578.39. The stock traded down 0.7% on Wednesday to GBX 2,153 with unusually high volume. Analysts currently have a "Hold" consensus rating for GSK with a target price of GBX 1,917.86.
2026-02-11 16:27:27
GSK insider Julie Brown recently acquired 6 shares of the company's stock on February 10th at a price of GBX 2,179 per share, totaling £130.74. This transaction comes as GSK share prices traded down to GBX 2,153 with high trading volume. Analysts currently have a mixed view on GSK, with a consensus "Hold" rating and an average price target of GBX 1,917.86.
2026-02-11 15:27:27
GSK announced that its senior executives, including CEO Luke Miels, Chief People Officer Diana Conrad, and Group General Counsel James Ford, vested their 2023 Deferred Annual Bonus Plan awards on February 9, 2026, after a three-year restriction period. Following the vesting, these executives sold a portion of their newly acquired GSK shares on the London Stock Exchange at just over £22 per share to cover tax liabilities. This action aligns executive compensation with long-term shareholder interests and conforms to GSK's approved 2022 remuneration policy.
2026-02-11 05:07:56
GSK's recent stock performance aligns with strong earnings, yet the statutory profit may not fully capture its potential due to a UK£1.5 billion reduction from unusual, likely one-off items. These unusual items suggest that future profits could be higher if they don't recur, indicating that GSK's reported profit might actually understate its true earnings capability. The company has also shown impressive earnings per share growth over the last year.
2026-02-10 16:27:56
GSK's RSV vaccine, Arexvy, has been accepted for regulatory review in China for adults aged 60 and older, with a decision expected in 2027. If approved, it would be the first vaccine available in China for preventing RSV-related lower respiratory tract disease in this age group, where RSV affects over six million people annually. The submission is supported by Phase III trial data in Chinese adults demonstrating safety and immunogenicity.
2026-02-10 14:27:56
GSK's RSV vaccine, Arexvy, has been accepted for regulatory review in China for adults aged 60 and older, with a decision expected in 2027. If approved, it would be the first vaccine available in China for preventing lower respiratory tract disease caused by RSV in this age group, which affects over six million people annually. The submission is supported by robust clinical data, including positive Phase III trial results in China demonstrating an acceptable safety profile and immunogenicity.
